Complementing cell lines

Details Complementing cell lines Complementing cell lines

2005-12-13

2005-12-13

Guzo, David (Department: 1636)

Chemistry: molecular biology and microbiology

Animal cell, per se ; composition thereof; process of...

C435S366000, C435S069100, C435S320100, C435S455000, C435S235100

Reexamination Certificate

active

06974695

ABSTRACT:
A packaging cell line capable of complementing recombinant adenoviruses based on serotypes from subgroup B, preferably adenovirus type 35. The cell line is preferably derived from primary, diploid human cells (e.g., primary human retinoblasts, primary human embryonic kidney cells and primary human amniocytes) which are transformed by adenovirus E1 sequences either operatively linked on one DNA molecule or located on two separate DNA molecules, the sequences being operatively linked to regulatory sequences enabling transcription and translation of encoded proteins. Also disclosed is a cell line derived from PER.C6 (ECACC deposit number 96022940), which cell expresses functional Ad35 E1B sequences. The Ad35-E1B sequences are driven by the E1B promoter or a heterologous promoter and terminated by a heterologous poly-adenylation signal. The new cell lines are useful for producing recombinant adenoviruses designed for gene therapy and vaccination. The cell line can also be used for producing human recombinant therapeutic proteins such as human growth factors and human antibodies. In addition, the cell lines are useful for producing human viruses other than adenovirus such as influenza virus, herpes simplex virus, rotavirus, measles virus.

REFERENCES:
patent: 4487829 (1984-12-01), Sharp et al.
patent: 4517686 (1985-05-01), Ruoslahti et al.
patent: 4578079 (1986-03-01), Ruoslahti et al.
patent: 4589881 (1986-05-01), Pierschbacher et al.
patent: 4593002 (1986-06-01), Dulbecco
patent: 4792525 (1988-12-01), Ruoslahti et al.
patent: 4797368 (1989-01-01), Carter et al.
patent: 4956281 (1990-09-01), Wallner et al.
patent: 5024939 (1991-06-01), Gorman
patent: 5096815 (1992-03-01), Ladner et al.
patent: 5166320 (1992-11-01), Wu et al.
patent: 5198346 (1993-03-01), Ladner et al.
patent: 5204445 (1993-04-01), Plow et al.
patent: 5223394 (1993-06-01), Wallner
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5240846 (1993-08-01), Collins et al.
patent: 5246921 (1993-09-01), Reddy et al.
patent: 5332567 (1994-07-01), Goldenberg
patent: 5349053 (1994-09-01), Landolfi
patent: 5403484 (1995-04-01), Ladner et al.
patent: 5436146 (1995-07-01), Shenk et al.
patent: 5443953 (1995-08-01), Hansen et al.
patent: 5474935 (1995-12-01), Chatterjee et al.
patent: 5521291 (1996-05-01), Curiel et al.
patent: 5534423 (1996-07-01), Palsson et al.
patent: 5543328 (1996-08-01), McClelland et al.
patent: 5547932 (1996-08-01), Curiel et al.
patent: 5552311 (1996-09-01), Sorscher et al.
patent: 5559099 (1996-09-01), Wickham et al.
patent: 5571698 (1996-11-01), Ladner et al.
patent: 5622699 (1997-04-01), Ruoslahti et al.
patent: 5712136 (1998-01-01), Wickham et al.
patent: 5731190 (1998-03-01), Wickham et al.
patent: 5770442 (1998-06-01), Wickham et al.
patent: 5837511 (1998-11-01), Falck-Pedersen et al.
patent: 5846782 (1998-12-01), Wickham et al.
patent: 5849561 (1998-12-01), Falck-Pedersen
patent: 5856152 (1999-01-01), Wilson et al.
patent: 5871727 (1999-02-01), Curiel
patent: 5871982 (1999-02-01), Wilson et al.
patent: 5877011 (1999-03-01), Armentano et al.
patent: 5880102 (1999-03-01), George et al.
patent: 5922315 (1999-07-01), Roy
patent: 5994128 (1999-11-01), Fallaux et al.
patent: 5994132 (1999-11-01), Chamberlain et al.
patent: 6033908 (2000-03-01), Bout et al.
patent: 6057155 (2000-05-01), Wickham et al.
patent: 6057158 (2000-05-01), Chamberlain et al.
patent: 6063622 (2000-05-01), Chamberlain et al.
patent: 6083750 (2000-07-01), Chamberlain et al.
patent: 6100086 (2000-08-01), Kaplan et al.
patent: 6127525 (2000-10-01), Crystal et al.
patent: 6238893 (2001-05-01), Hoeben et al.
patent: 6265212 (2001-07-01), Fallaux et al.
patent: 6287857 (2001-09-01), O'riordan et al.
patent: 6306652 (2001-10-01), Fallaux et al.
patent: 6395519 (2002-05-01), Fallaux et al.
patent: 6486133 (2002-11-01), Herlyn et al.
patent: 6492169 (2002-12-01), Vogels et al.
patent: 6669942 (2003-12-01), Perricaudet et al.
patent: 2002/0177544 (2002-11-01), Haack et al.
patent: 197 54 103 A 1 (1999-06-01), None
patent: 199 18 023 A 1 (2000-09-01), None
patent: 259212 (1987-08-01), None
patent: 1016726 (1998-12-01), None
patent: 0 950 713 (1999-10-01), None
patent: WO 91/00360 (1991-01-01), None
patent: WO 91/05805 (1991-05-01), None
patent: WO 91/05871 (1991-05-01), None
patent: WO 92/02553 (1992-02-01), None
patent: WO 92/13081 (1992-08-01), None
patent: WO 93/03769 (1993-03-01), None
patent: WO 93/06223 (1993-04-01), None
patent: WO 93/07282 (1993-04-01), None
patent: WO 93/07283 (1993-04-01), None
patent: WO 94/08026 (1994-04-01), None
patent: WO 94/10323 (1994-05-01), None
patent: WO 94/11506 (1994-05-01), None
patent: WO 94/15644 (1994-07-01), None
patent: WO 94/17832 (1994-08-01), None
patent: WO 94/24299 (1994-10-01), None
patent: WO 94/26915 (1994-11-01), None
patent: WO 95/05201 (1995-02-01), None
patent: WO 95/06745 (1995-03-01), None
patent: WO 95/14785 (1995-06-01), None
patent: WO 95/21259 (1995-08-01), None
patent: WO 95/26412 (1995-10-01), None
patent: WO 95/27071 (1995-10-01), None
patent: WO 95/31187 (1995-11-01), None
patent: WO 95/31566 (1995-11-01), None
patent: WO 96/00326 (1996-01-01), None
patent: WO 96/00790 (1996-01-01), None
patent: WO 96/07739 (1996-03-01), None
patent: WO 96/10087 (1996-04-01), None
patent: WO 96/12030 (1996-04-01), None
patent: WO 96/13597 (1996-05-01), None
patent: WO 96/13598 (1996-05-01), None
patent: WO 96/14837 (1996-05-01), None
patent: WO 96/17073 (1996-06-01), None
patent: WO 96/18740 (1996-06-01), None
patent: WO 96/24453 (1996-08-01), None
patent: WO 96/26281 (1996-08-01), None
patent: WO 96/35798 (1996-11-01), None
patent: WO 97/00326 (1997-01-01), None
patent: WO 97/12986 (1997-04-01), None
patent: WO 97/20575 (1997-06-01), None
patent: WO 97/38723 (1997-10-01), None
patent: WO 98/07865 (1998-02-01), None
patent: WO 98/11221 (1998-03-01), None
patent: WO 98/13499 (1998-04-01), None
patent: WO 98/17783 (1998-04-01), None
patent: WO 98/22609 (1998-05-01), None
patent: WO 98/32842 (1998-07-01), None
patent: WO 98/40509 (1998-09-01), None
patent: WO 98/49300 (1998-11-01), None
patent: WO 98/50053 (1998-11-01), None
patent: 1067188 (1999-07-01), None
patent: WO 99/32647 (1999-07-01), None
patent: WO 99/47180 (1999-09-01), None
patent: 102529 (1999-11-01), None
patent: WO 99/55132 (1999-11-01), None
patent: WO 99/58646 (1999-11-01), None
patent: WO 00/03029 (2000-01-01), None
patent: WO 00/24730 (2000-05-01), None
patent: WO 00/31285 (2000-06-01), None
patent: WO 00/52186 (2000-09-01), None
patent: WO 00/70071 (2000-11-01), None
patent: WO 01/04334 (2001-01-01), None
patent: WO 01/90158 (2001-11-01), None
patent: WO 02/24730 (2002-03-01), None
patent: WO 02/27006 (2002-04-01), None
patent: WO 02/40665 (2002-05-01), None
patent: WO 02/40665 (2002-05-01), None
Al. van Olphen and S. Mittal. “Development and Characterization of Bovine X Human Hybrid Cell Lines that Efficientlyy Support the Replication of both Wild-Type Bovine and Human Adenoviruses and Those with E1 Deleted.” J. of Virol., 2002, p. 5882-5892.
van Olphen, Albert, et al. “Characterization of Bovine Adenovirus Type 3 E1 Proteins and Isolation of E1-Expresing Cell Lines.” Virology, 295, p. 5882-5892, 2002.
Abrahamsen et al. “Construction of an Adenovirus Type 7a E1A- Vector.” J. of Virol., 1997, p. 8946-8951.
PCT International Search Report, PCT/NL01/00824, dated Jul. 19, 2002.
Schiedner et al., Abstract, Efficient transformation of primary human amniocytes by E1 functions of Ad5; generation of new cell lines for adenoviral vector production, Human Gene Therapy, Oct. 10, 2000, pp. 2105-2116, vol 11, No. 15.
Abrahamsen et al., “Construction of an Adenovirus Type 7a E1A Vector,” Journal of Virology, Nov. 1997, p. 8946-8951 vol. 71, No. 11.
Albiges-Rizo et al., “Human Adenovirus Serotype 3 Fiber Protein,” Journal of Biological Chemistry, 266(6), 3961-3967 (1991).
Anderson, Nature, “Human gene therapy,” Apr. 1998, vol. 392, pp. 25-30.
Athappilly et al., “The Refined Crystal Structure of Hexon, the Major Coat Protein of Adenovirus Type 2, at

Affiliated with

Also associated with

Rating

Complementing cell lines does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Complementing cell lines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Complementing cell lines will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3504747